Journal
JOURNAL OF MEDICAL VIROLOGY
Volume 93, Issue 5, Pages 3176-3183Publisher
WILEY
DOI: 10.1002/jmv.26880
Keywords
antiviral; COVID-19; mild cases
Categories
Funding
- Mansoura University [RP.20.05.69, mu-med-2020-26]
Ask authors/readers for more resources
This study compared the rate and time of viral clearance in patients receiving different treatments and found that patients in the combined antiviral group had a higher clearance rate.
This trial compared the rate and time of viral clearance in subjects receiving a combination of nitazoxanide, ribavirin, and ivermectin plus Zinc versus those receiving supportive treatment. This non-randomized controlled trial included 62 patients on the triple combination treatment versus 51 age- and sex-matched patients on routine supportive treatment. all of them confirmed cases by positive reverse-transcription polymerase chain reaction of a nasopharyngeal swab. Trial results showed that the clearance rates were 0% and 58.1% on the 7th day and 13.7% and 73.1% on the 15th day in the supportive treatment and combined antiviral groups, respectively. The cumulative clearance rates on the 15th day are 13.7% and 88.7% in the supportive treatment and combined antiviral groups, respectively. This trial concluded by stating that the combined use of nitazoxanide, ribavirin, and ivermectin plus zinc supplement effectively cleared the SARS-COV2 from the nasopharynx in a shorter time than symptomatic therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available